文献速递泌尿生殖MR

前列腺特异性抗原升高男性的简化双参数前列腺MR成像

Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen.
PubMed 文献 · Radiology · 2017-07-20

该回顾性研究纳入542例PSA≥3 ng/mL且经直肠超声引导穿刺阴性男性,比较简化双参数MRI与全多参数增强MRI对临床显著前列腺癌的诊断准确性,双参数MRI诊断准确性89.1%与全多参数87.2%相似,阅片者间一致性κ=0.81。

要点

  • 双参数MRI(轴位T2WI+DWI,<9分钟)诊断临床显著前列腺癌准确性89.1%,与全多参数增强MRI的87.2%相似。
  • 双参数MRI阅片者间一致性高(κ=0.81),适用于PI-RADS v2评分。
  • 双参数MRI无需注射对比剂,检查时间不足9分钟。

核心结论

  • 双参数MRI可检测经直肠超声引导穿刺漏诊的临床显著前列腺癌,其诊断准确性和癌症检出率与常规全多参数增强MRI方案相当。

研究设计与样本

  • 经机构审查委员会批准的回顾性分析,数据为前瞻性采集,纳入542例PSA≥3 ng/mL且经直肠超声引导穿刺阴性男性,年龄64.8岁±8.2(中位PSA 7 ng/mL),在3.0-T行全多参数增强MRI(无直肠内线圈,采集时间34分19秒),先仅阅轴位结构成像(T2WI turbo自旋回波和DWI,采集时间8分45秒,称双参数MRI)按PI-RADS v2诊断,再阅其余全多参数图像;PI-RADS 3-5类行MR引导靶向穿刺,1-2类泌尿科随访至少2年;另由3名放射科医师独立阅读100例双参数MRI评估阅片者间一致性。

诊断标准与关键数值

  • 双参数MRI检测临床显著前列腺癌的诊断为89.1%(483/542),全多参数增强MRI为87.2%(473/542);双参数MRI检出138例临床显著前列腺癌,全多参数增强MRI额外检出1例临床显著前列腺癌(pT2a期、中危、Gleason评分3+4)并导致11例额外假阳性诊断;双参数MRI阅片者间一致性κ=0.81。

临床应用与阅片要点

  • 双参数MRI检查时间不足9分钟且无需注射对比剂,其诊断准确性和癌症检出率与常规全多参数增强MRI方案相当;阅片按PI-RADS v2进行。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine the diagnostic accuracy for clinically significant prostate cancer achieved with abbreviated biparametric prostate magnetic resonance (MR) imaging in comparison with full multiparametric contrast material-enhanced prostate MR imaging in men with elevated prostate-specific antigen (PSA) and negative transrectal ultrasonography (US)-guided biopsy findings; to determine the significant cancer detection rate of biparametric versus full multiparametric contrast-enhanced MR imaging and between-reader agreement for interpretation of biparametric MR imaging. Materials and Methods In this institutional review board-approved retrospective review of prospectively acquired data, men with PSA greater than or equal to 3 ng/mL after negative transrectal US-guided biopsy findings underwent state-of-the-art, full multiparametric contrast-enhanced MR imaging at 3.0-T including high-spatial-resolution structural imaging in several planes, diffusion-weighted imaging at 0, 800, 1000, and 1400 mm2/sec, and dynamic contrast-enhanced MR imaging, obtained without endorectal coil within 34 minutes 19 seconds. One of four radiologists with different levels of expertise (1-9 years) first reviewed only a fraction of the full multiparametric contrast-enhanced MR images, consisting of single-plane (axial) structural imaging (T2-weighted turbo spin-echo and diffusion-weighted imaging), acquired within 8 minutes 45 seconds (referred to as biparametric MR imaging), and established a diagnosis according to the Prostate Imaging Reporting and Data System (PI-RADS) version 2; only thereafter, the remaining full multiparametric contrast-enhanced MR images were read. Men with PI-RADS categories 3-5 underwent MR-guided targeted biopsy. Men with PI-RADS categories 1-2 remained in urologic follow-up for at least 2 years, with rebiopsy (transrectal US-guided or transperineal saturation) where appropriate. McNemar test was used to compare diagnostic accuracies. To investigate between-reader agreement, biparametric MR images of 100 patients were read independently by all three radiologists. Results A total of 542 men, aged 64.8 years ± 8.2 (median PSA, 7 ng/mL), were included. Biparametric MR imaging helped detect clinically significant prostate cancer in 138 men. Full multiparametric contrast-enhanced MR imaging allowed detection of one additional clinically significant prostate cancer (a stage pT2a, intermediate-risk cancer with a Gleason score of 3+4) and caused 11 additional false-positive diagnoses. Diagnostic accuracy for detection of clinically significant cancer of biparametric MR imaging (89.1%, 483 of 542) was similar to that of full multiparametric contrast-enhanced MR imaging (87.2%, 473 of 542). Between-reader agreement of biparametric MR imaging interpretation was substantial (κ = 0.81). Conclusion Biparametric MR imaging allows detection of clinically significant prostate cancer missed by transrectal US-guided biopsy. Biparametric prostate MR imaging takes less than 9 minutes examination time, works without contrast agent injection, and offers a diagnostic accuracy and cancer detection rate that are equivalent to those of conventional full multiparametric contrast-enhanced MR imaging protocols. © RSNA, 2017.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kuhl CK, Bruhn R, Krämer N, et al. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. Radiology. 2017. PMID: 28727544. doi:10.1148/radiol.2017170129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。